At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 547 enrolled
Drug / intervention
BDP Nasal Aerosol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week, Clinical Study Designed to Assess the Efficacy and Safety of BDP Nasal Aerosol (80 mcg, Once Daily) in Pediatric Subjects (4 to 11 Years of Age) With PAR
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Feb 5, 2013·Updated Oct 12, 2015
In Brief
A Phase 3 clinical trial evaluating BDP Nasal Aerosol and Placebo for Allergic Rhinitis. Completed, enrolled 547 participants across 63 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of Beclomethasone dipropionate (BDP) nasal aerosol in subjects with Perennial Allergic Rhinitis (PAR).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2013
First PostedFeb 2013
Primary CompletionOct 2013
TodayJul 2026
First PostedFeb 5, 2013
Enrollment StartJan 1, 2013
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 13.4 years ago
Interventions
BDP Nasal Aerosoldrug
Placebodrug